Healthcare Sector Analysis

224 tickers in Healthcare
Ranks this page's recent reports by score.
Henry Schein, Inc.
HSIC·Healthcare
A ★★★★Buy
Current$85.31
Target$98.60
Return+15.6%
Nov 6, 2026

Henry Schein offers a healthcare distribution earnings-recovery opportunity supported by share gains, margin expansion, and buybacks, although elevated leverage and modest returns on invested capital constrain its upside.

Score
75
Mirum Pharmaceuticals, Inc.
MIRM·Healthcare
B ★★★Hold
Current$93.54
Target$104.00
Return+11.2%
Nov 6, 2026

Mirum's expanding rare-disease drug portfolio and late-stage pipeline support sustained commercial growth, but substantial dilution, negative recent cash flow, and demanding valuation limit near-term investment appeal.

Score
65
Revvity, Inc.
RVTY·Healthcare
B ★★★Hold
Current$150.83
Target$152.50
Return+1.1%
Nov 6, 2026

Revvity's specialized life-sciences and diagnostics franchises offer improving organic growth and strong cash generation, but elevated valuation multiples and weak reported returns on capital limit near-term upside.

Score
69
Waters Corporation
WAT·Healthcare
B ★★★Hold
Current$453.08
Target$472.50
Return+4.3%
Nov 6, 2026

Waters combines durable laboratory instrumentation, recurring consumables, and expanding diagnostics exposure with meaningful synergy opportunities, but elevated leverage and demanding cash-flow expectations limit its near-term investment appeal.

Score
68
Pfizer Inc.
PFE·Healthcare
A ★★★★Buy
Current$29.88
Target$32.01
Return+7.1%
Nov 6, 2026

Pfizer offers attractive dividend income and potential upside from innovative medicines at a moderate cash-flow valuation, although patent expirations and significant acquisition-related debt could constrain future earnings growth.

Score
79
Amgen Inc.
AMGN·Healthcare
B ★★★Hold
Current$460.28
Target$442.62
Return-3.8%
Nov 6, 2026

Amgen combines a durable biotechnology franchise, strong cash generation, and growing specialty medicines, but elevated valuation, biosimilar erosion, and acquisition-related leverage constrain prospective returns.

Score
67
Fresenius Medical Care AG
FMS·Healthcare
A ★★★★Buy
Current$23.66
Target$26.40
Return+11.6%
Nov 6, 2026

Fresenius Medical Care offers durable dialysis demand, strong free cash flow, and buyback-supported earnings recovery at a modest valuation, although reimbursement pressure, weak treatment volumes, and restructuring execution remain significant risks.

Score
77
Teva Pharmaceutical Industries Limited
TEVA·Healthcare
C ★★Sell
Current$41.78
Nov 6, 2026

Teva's innovative medicines and deleveraging support a credible pharmaceutical turnaround, but its substantial rerating, persistent generic erosion, and demanding cash-flow expectations weaken the investment case.

Score
56
Travere Therapeutics, Inc.
TVTX·Healthcare
B ★★★Hold
Current$52.42
Target$64.56
Return+23.2%
Nov 5, 2026

Travere Therapeutics can create substantial value through FILSPARI's expanding IgAN and FSGS franchise, but concentrated product exposure, uneven profitability, and demanding commercial expectations limit the margin of safety.

Score
69
Neurocrine Biosciences, Inc.
NBIX·Healthcare
A ★★★★Buy
Current$166.03
Target$203.49
Return+22.6%
Nov 5, 2026

Neurocrine combines strong commercial cash generation with growing rare-disease franchises and promising psychiatric pipeline assets, although INGREZZA concentration, acquisition economics, and clinical failures remain key risks.

Score
81
BioMarin Pharmaceutical Inc.
BMRN·Healthcare
B ★★★Hold
Current$57.13
Target$70.40
Return+23.2%
Nov 5, 2026

BioMarin offers a differentiated rare-disease portfolio with expanding commercial opportunities and attractive normalized valuation, but acquisition leverage and uncertain earnings recovery constrain near-term investment conviction.

Score
66
Waystar Holding Corp.
WAY·Healthcare
A ★★★★Buy
Current$29.69
Target$33.15
Return+11.7%
Nov 5, 2026

Waystar offers durable healthcare payment software growth through recurring subscriptions, embedded customer workflows, and automation, although dilution, leverage, and competition could constrain per-share returns.

Score
76